Josep M. Llovet, MD

Josep M. Llovet, MD, Mount Sinai

Articles by Josep M. Llovet, MD

LEAP-012: PFS Benefit With Pembrolizumab, Levatinib, and TACE vs TACE Alone

Josep M. Llovet, MDGI Cancer | March 13, 2025

Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.

LEAP-002: IO/VEGF Versus IO/IO Versus IO/TKI

Josep M. Llovet, MDHepatocellular Carcinoma | March 13, 2025

Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.

LEAP-002: Lenvatinib Plus Pembrolizumab for First-Line Advanced HCC?

Josep M. Llovet, MDHepatocellular Carcinoma | March 13, 2025

Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.